HUNAN FANGSHENG PHARMACEUTICAL CO., LTD.

Hunan Fangsheng Pharmaceutical Co., Ltd.

603998

CNE100001VG6

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
12.03 ^CNY	-0.74%		-3.37%	+9.76%

Apr. 19	Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 10	Fangsheng Pharma's Factories Pass GMP Inspection	MT

Guo Jianjun agree to acquire 50% stake in Hunan Hengxing Pharmaceutical Technology Co., Ltd. from Hunan Fangsheng Pharmaceutical Co., Ltd. for CNY 9.4 million.

December 17, 2021

Guo Jianjun agree to acquire 50% stake in Hunan Hengxing Pharmaceutical Technology Co., Ltd. from Hunan Fangsheng Pharmaceutical Co., Ltd. (SHSE:603998) for CNY 9.4 million on December 16, 2021. Hengxing Pharmaceutical Technology reported total assets of CNY 25.9 million and total common equity of CNY 15.7 million till September 30, 2021.

Latest news about Hunan Fangsheng Pharmaceutical Co., Ltd.

Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 19	CI
Fangsheng Pharma's Factories Pass GMP Inspection	Apr. 10	MT
Fangsheng Pharma Gets 12.1 Million Yuan in Government Grants in January-March	Apr. 08	MT
Fangsheng Pharma Withdraws Drug Registration Application For Headache Treatment	Dec. 01	MT
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-25	CI
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-20	CI
Fangsheng Pharma's Drugs Placed in 2022 Chinese Drug Catalogue	23-01-20	MT
Hunan Fangsheng Pharmaceutical Sees Up to 357% Surge in 2022 Profit; Shares Jump 3%	23-01-19	MT
Hunan Fangsheng Pharma Unit to Resume Work After Leakage Forces Suspension	22-12-15	MT
Hunan Fangsheng Pharmaceutical's Chinese Medicine Extraction Line Passes Regulatory Inspection	22-12-06	MT
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-30	CI
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-30	CI
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-28	CI
Hunan Fangsheng Pharmaceutical Co., Ltd. announced that it expects to receive CNY 269.999999 million in funding	22-03-03	CI
Hunan Fangsheng Pharmaceutical Co., Ltd. announced a financing transaction	22-03-03	CI
Hunan Fangsheng Ruixin Pharmaceutical Co., Ltd. announced that it expects to receive CNY 160 million in funding from Hunan Fangsheng Pharmaceutical Co., Ltd., Changsha Xingchen Kangrui Venture Capital Partnership Enterprise (Limited Partnership), and another investor	21-12-29	CI
China shares end lower as rising local COVID-19 cases drag consumer firms	21-12-27	RE
Guo Jianjun agree to acquire 50% stake in Hunan Hengxing Pharmaceutical Technology Co., Ltd. from Hunan Fangsheng Pharmaceutical Co., Ltd. for CNY 9.4 million.	21-12-17	CI
Yunnan Fuya Biotechnology Co., Ltd. announced that it expects to receive CNY 80 million in funding from Hunan Fangsheng Pharmaceutical Co., Ltd., Hong Kong TongSheng Industrial Co., Ltd.	21-12-15	CI
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-29	CI
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-26	CI
Hunan Fangsheng Pharmaceutical Co., Ltd. agreed to acquire Jiangxi Tengwangge Pharmaceutical Co., Ltd from Hunan Fangsheng Pharmaceutical Co., Ltd., Hunan Yuanhuixuan Management Consulting Co., Ltd and Guangzhou Changyixing Investment Management Co., Ltd for CNY	21-05-24	CI
He Ye entered into share transfer agreement to acquire 51% stake in Yingkou Sanhua Pharmaceutical Co., Ltd. from Hunan Fangsheng Pharmaceutical Co., Ltd. for CNY 24 million	21-05-24	CI

Chart Hunan Fangsheng Pharmaceutical Co., Ltd.

Duration

Period

Chart Hunan Fangsheng Pharmaceutical Co., Ltd.

More charts

Company Profile

Hunan FangshengPharmaceutical Co., Ltd. is a China-based company principally engaged in the research, development, production and sale of cardiovascular medicine, orthopedic medicine, pediatric medicine, gynecological medicine and anti-infective medicine. The Company's main products include Xuesaitong Dispersible Tablets, Xuesaitong Tablets, Tenghuang Jiangu Tablets, Dieda Huoxue Capsules, Lysine Dimension B12 Granules, Cefixoxime Tablets and Jinying Capsules. The Company distributes its products primarily in domestic market.

Sector

Pharmaceuticals

Calendar

2024-08-28 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Hunan Fangsheng Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.03 CNY

Average target price

10.31 CNY

Spread / Average Target

-14.30%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
HUNAN FANGSHENG PHARMACEUTICAL CO., LTD.	+9.76%	732M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.63%	44.11B
OTSUKA HOLDINGS CO., LTD.	+23.03%	22.71B
SANDOZ GROUP AG	+18.22%	15.15B
CIPLA LIMITED	+12.66%	13.56B
ZYDUS LIFESCIENCES LIMITED	+60.18%	12.7B
ONO PHARMACEUTICAL CO., LTD.	-10.02%	6.84B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+12.92%	5.63B

Generic Pharmaceuticals

Hunan Fangsheng Pharmaceutical Co., Ltd.

Equities

603998

CNE100001VG6

Pharmaceuticals

Guo Jianjun agree to acquire 50% stake in Hunan Hengxing Pharmaceutical Technology Co., Ltd. from Hunan Fangsheng Pharmaceutical Co., Ltd. for CNY 9.4 million.

Latest news about Hunan Fangsheng Pharmaceutical Co., Ltd.

Chart Hunan Fangsheng Pharmaceutical Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Hunan Fangsheng Pharmaceutical Co., Ltd.

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Generic Pharmaceuticals